An SCD patient in Bahrain received the gene-editing therapy Casgevy, marking the first time the treatment has been given outside the U.S.

CRISPR Therapeutics CRSP stock rose more than 25% in the past week, thanks to the encouraging fourth-quarter 2024 results and ...

The high cost of sickle cell gene therapies is pushing private insurers and Medicaid programs to develop new payment models.

The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in the NHS. It means that eligible SCD ...

HRH Prince Salman highlighted the Kingdom’s medical milestone in successfully completing the treatment of the world’s first sickle cell disease patient outside the US with Casgevy (exagamglogene ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

His Royal Highness Prince Salman bin Hamad Al Khalifa, the Crown Prince and Prime Minister, reaffirmed Bahrain’s commitment ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...